ReviewPediatric radiology2022
Gadolinium retention: should pediatric radiologists be concerned, and how to frame conversations with families.
Review in Pediatric radiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 19 citations in OpenAlex.
- Pediatric endocrine disorders: a review of intracranial findings and appropriate imaging.Pediatric radiology · 2026Review
- MRI scoring of pleural findings in cystic fibrosis does not require intravenous contrast media.European radiology · 2026Article
- Streamlining pediatric musculoskeletal infection workup: the why, what, and how of rapid MRI protocols.Pediatric radiology · 2026Review
- The Safety of Ultrasound Contrast Agents in Children.Diagnostics (Basel, Switzerland) · 2026Article
- Magnetic resonance urography (MRU): technique mastery and illustrative case reviews.Abdominal radiology (New York) · 2026Review
- Surveying Current Practices in the Use of Gadolinium-Based Contrast Agents for Routine Brain Magnetic Resonance Imaging in the Evaluation of Isolated Growth Hormone Deficiency among US Pediatric Endocrinologists.Hormone research in paediatrics · 2026Article
- Use of gadolinium-based contrast agents in multiple sclerosis: a review by the ESMRMB-GREC and ESNR Multiple Sclerosis Working Group.European radiology · 2024Review
- Fluid-attenuated inversion-recovery sequence with fat suppression as an alternative to contrast-enhanced MRI in pediatric synovitis.Pediatric radiology · 2024Article
- Utility of Gadolinium-Based Contrast in Initial Evaluation of Seizures in Children Presenting Emergently.AJNR. American journal of neuroradiology · 2023Article
- Advanced Neuromonitoring Modalities on the Horizon: Detection and Management of Acute Brain Injury in Children.Neurocritical care · 2023Review
- Comparison of the different imaging modalities used to image pediatric oncology patients: A COG diagnostic imaging committee/SPR oncology committee white paper.Pediatric blood & cancer · 2023Article
- Utility of Gadolinium Use in the Imaging Follow-Up of Nonenhancing Primary Brain Neoplasms in Children.Cureus · 2022Article
- Molecular MRI quantification of extracellular aldehyde pairs for early detection of liver fibrogenesis and response to treatment.Science translational medicine · 2022Article
- Tumor load rather than contrast enhancement is associated with the visual function of children and adolescents with optic pathway glioma - a retrospective Magnetic Resonance Imaging study.Journal of neuro-oncology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gadolinium retention in the brain and other organs has recently been identified by imaging and confirmed histologically. No direct clinical effects of gadolinium retention, which occurs after gadolinium-based contrast agent (GBCA) administration for MRI, have been scientifically accepted at this time. However, there is understandable concern among medical professionals and the public about the potential effects of gadolinium retention, particularly in the brain. Part of this concern might stem from the identification of nephrogenic systemic fibrosis caused by GBCAs in people with severe renal failure in 2006. This article briefly describes the characteristics of GBCAs; reviews and differentiates gadolinium retention, nephrogenic systemic fibrosis, and "gadolinium deposition disease" or "gadolinium toxicity"; and discusses societal guidelines and current usage in children. With the belief that GBCAs should not be withheld for appropriate indications in the absence of evidence of its potential risks, we offer a framework for determining when GBCA use is appropriate and suggestions for discussing its risks and benefits with children and their families.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.